Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CHA Medical Group (often referred to as CHA Medical & Bio Group / CHA Health Systems) operates a large global network of hospitals and research centers and has advanced clinical programs in cell and gene therapy. Its stem cell therapy for degenerative disc herniation is in Phase 2a clinical trials, and it reports extended survival (>2 years in >40% of treated patients) in relapsed glioblastoma compared with typical 6–8 month survival, alongside multiple ongoing stem cell and immune cell–based clinical studies[5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CHA Medical Group.